RCS - Angle PLC - HER2 presentation at SABCS

AngleAnnouncement

13/12/2024 08:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241213:nRSM0321Qa&default-theme=true

RNS Number : 0321Q  Angle PLC  13 December 2024

 For immediate release  13 December 2024

 

ANGLE plc ("the Company")

 

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST
CANCER SYMPOSIUM

 

Independent findings support ANGLE's HER2 assay development programme

 

Potential for stratification of breast cancer patients for treatment with HER2
antibody drug conjugates

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the presentation of
an independent study, reporting on a novel, Parsortix(®)-based human
epidermal growth factor receptor 2 (HER2) workflow at the prominent San
Antonio Breast Cancer Symposium being held from 10 to 13 December 2024.

 

The findings, published by Weill Cornell Medicine, corroborate ANGLE's own
findings from its HER2 assay development programme, and provide a
semi-automated solution which may help to accelerate adoption of CTC-based
HER2 tests. HER2 status is known to change in a significant proportion of
breast cancer patients over time, so a minimally invasive, real-time assay is
needed for dynamic HER2 assessment to enable targeted treatment selection and
detection of emerging treatment resistance or progression.

 

HER2 is a protein that is associated with many cancers, and HER2 tumour
marker testing is used to determine if targeted therapy will be effective. A
quantitative HER2 test, that objectively measures HER2 expression levels,
enables the identification of patients who are HER2-high, intermediate or low
and therefore suitable for treatment with HER2-antibody drug conjugates
(ADCs).

 

The poster reports on a study in 16 patients with metastatic breast cancer, in
which the Parsortix system was used to isolate and harvest CTCs and
CTC-clusters prior to automated imaging and classification as HER2-high,
intermediate, low or negative. Using the Parsortix system, CTCs were
identified in 100% of patients and their HER2 status classified.  Importantly
the study identified patients with HER2 expressing CTCs that had a
HER2-negative tissue biopsy.

 

Over 60% of breast cancer patients have a HER2-negative tissue biopsy when
diagnosed and, as a result, are currently excluded from prescription of HER2
targeted ADCs.  The workflow presented in this poster has the potential to be
used to assess the current HER2 status of these patients and identify those
whose HER2 status has changed making them eligible for the treatment.

 

Dr. Carolina Reduzzi, Assistant Professor of Cancer Biology Research in
Medicine, Weill Cornell Medicine commented:

"We are pleased to present further data validating our workflow which enables
quantitative and semi-automated assessment of HER2 in CTCs. HER2 is a major
therapeutic target and an accurate and real-time assessment of HER2 status
could be used to monitor CTCs over time to better guide treatment and identify
patients with any detectable HER2 expression, or changes to HER2 expression,
who could benefit from treatment with ADCs.

 

This methodology has the potential to be applied to a wide range of biomarkers
and our ultimate goal is to develop automated workflows which enable
longitudinal CTC assessment of biomarker status for targeted treatment
selection or to predict treatment response."

 

ANGLE's Chief Scientific Officer, Karen Miller, commented:

"We are pleased to see new data that supports the utility of quantitative HER2
assessment on CTCs isolated using the Parsortix system and independently
validates ANGLE's own findings from our HER2 assay development programme. HER2
status is known to change in up to 38% of breast cancer patients. As such
real-time quantitative HER2 assessment is crucial for both effective treatment
and to support patient stratification for clinical trials and insight into
dynamic changes in HER2 status which may correlate to therapeutic response."

 

The poster is available at: https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/)

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

All results reported in this announcement and any other products and services
are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVXLBFZLLZFBX